NervGen Pharma Corp.
NGEN
$3.57
-$0.15-3.91%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -213.86% | 24.76% | -15.05% | -58.14% | 2.81% |
| Total Depreciation and Amortization | -11.50% | -5.61% | -8.18% | -65.85% | -60.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 395.84% | -540.69% | 42.49% | 54.50% | -21.54% |
| Change in Net Operating Assets | -126.03% | 40.22% | 88.84% | 90.98% | 146.06% |
| Cash from Operations | -75.52% | 8.47% | 13.30% | -19.15% | -15.25% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 0.56% | -1.08% | 198.36% | -- | -- |
| Cash from Investing | 0.56% | -1.08% | 198.36% | -- | -- |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Issuance of Common Stock | 4,963.99% | 273.22% | 2,901.40% | -92.55% | 235.20% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -427.74% | 71.29% | -- |
| Cash from Financing | 5,321.67% | 265.32% | 4,124.97% | -94.56% | 302.73% |
| Foreign Exchange rate Adjustments | 181.03% | 86.30% | -71.73% | 119.09% | -253.09% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 387.36% | 23.11% | 131.79% | -114.09% | -16.30% |